Skip to main content

Table 4 AURKA is associated with metastasis-free survival (MFS) in three independent cohorts of systemically untreated node negative breast cancer (combined Mainz, Rotterdam and Transbig cohorts, n=766)

From: Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients

  Mainz cohort (n=200) Rotterdam cohort (n=286) Transbig cohort (n=280) Combined cohorts (n=766)
A. Univariate Cox analysis
AURKA P-value <0.001 <0.001 0.005 <0.001
HR 1.927 1.952 1.520 1.669
95%-CI 1.335-2.782 1.448-2.632 1.135-2.036 1.402-1.986
B. Multivariate Cox analysis of MFS adjusted to established clinical factors (combined Mainz and Transbig cohorts, n=465)
  p HR 95 % CI
Age (<50 vs. ≥50 years) 0.392 1.180 0.808-1.726
pT stage (≤2cm vs. >2cm) 0.005 1.812 1.192-2.754
Histological grade (Grade 1 and 2 vs. grade 3) 0.087 1.529 0.940-2.487
ER status (negative vs. positive) 0.413 1.214 0.763-1.931
HER2 status (negative vs. positive) 0.415 1.248 0.732-2.128
AURKA (continuous variable) 0.046 1.350 1.005-1.812
  1. HR: hazards ratio, 95%-CI: 95% confidence interval. AURKA was analyzed as a continuous variable.